Business Context and Reporting Period
This Form 8-K Current Report was filed by Aptevo Therapeutics Inc. on June 22, 2017, covering events occurring on June 17 and June 19, 2017. The filing details the entry into material definitive agreements regarding the commercial supply of the company's IXINITY product and amendments to a co-development agreement for MOR209/ES414.
Key Financial Metrics and Agreements
- Commercial Supply Agreement: Aptevo Biotherapeutics LLC entered into an Amended and Restated Commercial Supply Agreement with CMC ICOS Biologics, Inc. for the manufacture of IXINITY.
- Manufacturing Forecast: Starting in 2018, the agreement mandates a minimum of four batches and a maximum of ten batches per calendar year based on a 24-month rolling forecast.
- Financial Reserve: A $7.0 million reserve held by CMC is designated to be applied to batches manufactured through the end of 2017. Any remaining balance must be paid to Aptevo Bio by December 31, 2017.
- Agreement Term: The supply agreement has an initial five-year term, renewable for successive two-year terms with 24 months' prior notice.
- Development Cost Sharing: Under the Fourth Amendment to the License and Co-Development Agreement with MorphoSys AG, cost-sharing for MOR209/ES414 shifts over time:
- Until August 31, 2017: Aptevo bears 75%, MorphoSys bears 25%.
- September 1, 2017 to December 31, 2018: Aptevo bears 49%, MorphoSys bears 51%.
- From January 1, 2019: Aptevo bears 36%, MorphoSys bears 64%.
Material Changes and Unusual Items
The filing supersedes the original supply agreement dated June 17, 2011. A significant change involves the revised termination rights for MorphoSys, which now allows termination for convenience within one week of receiving certain test results or at any time during the last two weeks of August 2017. The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period.
Guidance, Outlook, and Risks
Management commentary is limited to the terms of the new agreements. The primary risk identified is the enhanced termination right granted to MorphoSys, which could end the collaboration for MOR209/ES414 based on specific test results or a fixed timeline in August 2017. The filing notes that the descriptions of the agreements are qualified by reference to the full text of the documents, which will be filed as exhibits to the Form 10-Q for the quarter ending June 30, 2017.
Investor Verification Checklist
- Verify the status of the $7.0 million reserve held by CMC and the expected payout date.
- Review the full text of the Fourth Amendment to understand the specific "test results" that trigger MorphoSys's termination right.
- Confirm the 2018 batch forecast numbers for IXINITY to assess future manufacturing costs.
- Monitor the Form 10-Q for the quarter ending June 30, 2017, for the complete legal text of the agreements.